Status and phase
Conditions
Treatments
About
Patients with hemorrohoids grade II and III were included. Patients were randomized into 2 groups:
Bleeding, pain and stinging will be evaluated 14 days after beginning the treatment.
Full description
Patients with hemorrohoids grade II and III were included.
Patients were randomized into 2 groups:
Bleeding, pain and stinging will be evaluated 14 days after beginning the treatment. Quantification of pain will be performed following a visual analogic scale ranging from 0 (absence of symptoms) to 100 (unbearable symptoms).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 2 patient groups
There are currently no registered sites for this trial.
Central trial contact
Jaime Ruiz-Tovar; Carolina LLavero Garrido
Start date
May 01, 2020 • 4 years ago
End date
Oct 30, 2020 • 4 years ago
Today
Apr 05, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal